

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/083182 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 211/66**,  
413/12, A61K 31/4468, 31/536, A61P 37/00

Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridge-  
bury Road, P.O. Box 368, Ridgefield, CT 06877-0368  
(US).

(21) International Application Number:  
PCT/US2004/006554

(74) Agents: **RAYMOND, Robert, P.** et al.; Boehringer In-  
gelheim Corporation, 900 Ridgebury Road, P.O. Box 368,  
Ridgefield, CT 06877-0368 (US).

(22) International Filing Date: 3 March 2004 (03.03.2004)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(26) Publication Language: English

(30) Priority Data:  
60/454,239 13 March 2003 (13.03.2003) US

(71) Applicant (for all designated States except US):  
**BOEHRINGER INGELHEIM PHARMACEUTI-  
CALS, INC.** [US/US]; 900 Ridgebury Road, P.O. Box  
368, Ridgefield, CT 06877-0368 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HICKEY, Eugene,  
R.** [US/US]; Boehringer Ingelheim Pharmaceuticals,  
Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT  
06877-0368 (US). **LIU, Wiemen** [CN/US]; Boehringer  
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road,  
P.O. Box 368, Ridgefield, CT 06877-0368 (US). **SUN,  
Sanxing** [CN/US]; Boehringer Ingelheim Pharmaceu-  
ticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield,  
CT 06877-0368 (US). **WARD, Yancey, David** [US/US];  
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridge-  
bury Road, P.O. Box 368, Ridgefield, CT 06877-0368  
(US). **YOUNG, Erick, Richard, Roush** [US/US];


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**


- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

[Continued on next page]

(54) Title: CATHEPSIN S INHIBITORS



(I)



(II)

(57) Abstract: This invention relates to peptidyl compounds of the formulas (I) and (II) active as cathepsin S, a cysteine protease, inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are therefore useful in the treatment of autoimmune and other diseases. The invention also relates to processes for preparing such compounds and pharmaceutical compositions comprising them.

**BEST AVAILABLE COPY**

WO 2004/083182 A1



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## Cathepsin S Inhibitors

### APPLICATION DATA

This application claims benefit to US provisional application no. 60/454,239 filed

5 03/13/2003.

### TECHNICAL FIELD OF THE INVENTION

This invention relates to peptidyl compounds active as cathepsin S, a cysteine protease,  
10 inhibitors. The compounds are selective, reversible inhibitors of the cathepsin S are  
therefore useful in the treatment of autoimmune and other diseases. The invention also  
relates to processes for preparing such compounds and pharmaceutical compositions  
comprising them.

15

### BACKGROUND OF THE INVENTION

Cathepsin S is a member of the papain family, within the papain superfamily of cysteine  
proteases. The papain family is the largest group of cysteine proteases and includes  
proteases such as cathepsins B, H, K, L, O and S. (A.J. Barrett et al., 1996, Perspectives  
20 in Drug Discovery and Design, 6, 1). The cysteine proteases have important roles in  
human biology and diseases including atherosclerosis, emphysema, osteoporosis, chronic  
inflammation and immune disorders (H.A. Chapman et al., 1997, Ann. Rev. Physiol., 59,  
63). Cathepsin S plays a key role in regulating antigen presentation and immunity (H.A.  
Chapman, 1998, Current Opinion in Immunology, 10, 93; R. J. Riese et al., 1998, J. Clin.  
25 Invest., 101, 2351; R.J. Riese et al., 1996, Immunity, 4, 357). Cathepsin S deficient mice  
have impaired invariant chain degradation resulting in decreased antigen presentation and  
germinal center formation, and diminished susceptibility to collagen-induced arthritis  
indicating the therapeutic potential for a cathepsin S inhibitor (G. Shi et al., 1999,  
Immunity, 10, 197; T.Y. Nakagawa et al, 1999, Immunity, 10, 207)

30

The specificity of the immune response relies on processing of foreign protein and presentation of antigenic peptide at the cell surface. Antigenic peptide is presented bound to MHC Class II, a heterodimeric glycoprotein expressed in certain antigen presenting cells of hematopoietic lineage, such as B cells, macrophages and dendritic cells.

- 5 Presentation of antigen to effector cells, such as T-cells, is a fundamental step in recognition of non-self and thus initiation of the immune response.

Recently MHC Class II heterodimers were shown to associate intracellularly with a third molecule designated invariant chain. Invariant chain facilitates Class II transport to the  
10 endosomal compartment and stabilizes the Class II protein prior to loading with antigen. Invariant chain interacts directly with Class II dimers in the antigen-binding groove and therefore must be proteolyzed and removed or antigen cannot be loaded or presented. Current research suggests that invariant chain is selectively proteolyzed by cathepsin S, which is compartmentalized with MHC Class II complexes within the cell. Cathepsin S  
15 degrades invariant chain to a small peptide, termed CLIP, which occupies the antigen – binding groove. CLIP is released from MHC Class II by the interaction of MHC Class II with HLA-DM, a MHC-like molecule thus freeing MHC Class II to associate with antigenic peptides. MHC Class II-antigen complexes are then transported to the cell surface for presentation to T-cells, and initiation of the immune response.

20

Cathepsin S, through proteolytic degradation of invariant chain to CLIP, provides a fundamental step in generation of an immune response. It follows that inhibition of antigen presentation via prevention of invariant chain degradation by cathepsin S could provide a mechanism for immuno-regulation. Control of antigen-specific immune  
25 responses has long been desirable as a useful and safe therapy for autoimmune diseases. Such diseases include Crohn's disease and arthritis, as well as other T-cell-mediated immune responses (C. Janeway and P. Travers, 1996, Immunobiology, The Immune System in Health and Disease, Chapter 12). Furthermore, cathepsin S, which has broad pH specificity, has been implicated in a variety of other diseases involving extracellular  
30 proteolysis, such as Alzheimer's disease (U. Muller-Ladner et al., 1996, Perspectives in

Drug Discovery and Design, 6, 87), atherosclerosis (G.K. Sukhova et al., 1998, J. Clin. Invest., 102, 576) and endometriosis (WO 9963115, 1999).

5 A cathepsin S inhibitor has been found to block the rise in IgE titers and eosinophil infiltration in the lung in a mouse model of pulmonary hypersensitivity, suggesting that cathepsin S may be involved in asthma (R.J. Riese et al., J. Clin. Investigation, 1998, 101, 2351).

10 Cysteine proteases are characterized by having a cysteine residue at the active site which serves as a nucleophile. The active site also contains a histidine residue. The imidazole ring on the histidine serves as a base to generate a thiolate anion on the active site cysteine, increasing its nucleophilicity. When a substrate is recognized by the protease, the amide bond to be cleaved is directed to the active site, where the thiolate attacks the carbonyl carbon forming an acyl-enzyme intermediate and cleaving the amide bond,  
15 liberating an amine. Subsequently, water cleaves the acyl-enzyme species regenerating the enzyme and liberating the other cleavage product of the substrate, a carboxylic acid.

Inhibitors of cysteine proteases contain a functionality that can react reversibly or irreversibly with the active site cysteine. Examples of reactive functionalities that have  
20 been described (D. Rasnick, 1996, Perspectives in Drug Discovery and Design, 6, 47) on cysteine protease inhibitors include peptidyl diazomethanes, epoxides, monofluoroalkanes and acyloxymethanes, which irreversibly alkylate the cysteine thiol. Other irreversible inhibitors include Michael acceptors such as peptidyl vinyl esters and other carboxylic acid derivatives (S. Liu et al., J. Med Chem., 1992, 35, 1067) and vinyl  
25 sulfones (J.T. Palmer et al., 1995, J. Med Chem., 38, 3193).

Reactive functionalities that form reversible complexes with the active site cysteine include peptidyl aldehydes (R.P. Hanzlik et al., 1991, Biochim. Biophys. Acta., 1073, 33), which are non-selective, inhibiting both cysteine and serine proteases as well as  
30 other nucleophiles. Peptidyl nitriles (R.P. Hanzlik et al., 1990, Biochim. Biophys. Acta., 1035, 62) are less reactive than aldehydes and therefore more selective for the more

nucleophilic cysteine proteases. Various reactive ketones have also been reported to be reversible inhibitors of cysteine proteases (D. Rasnick, 1996, *ibid*). In addition to reacting with the nucleophilic cysteine of the active site, reactive ketones may react with water, forming a hemiketal which may act as a transition state inhibitor.


5

Examples of cathepsin S inhibitors have been reported. J.L. Klaus et al. (WO 96/40737) described reversible inhibitors of cysteine proteases including cathepsin S, containing an ethylene diamine. In US Patent No. 5,776,718 to Palmer et al. there is disclosed in it's broadest generic aspect a protease inhibitor comprising a targeting group linked through a two carbon atom chain to an electron withdrawing group (EWG). The compounds of the present application are structurally distinct and thus excluded from the 5,776,718 patent with particular embodiments possessing unexpectedly greater activity than the closest compounds of the prior art. US 6,353,017 describes dipeptide nitriles asserted to have activity as inhibitors of Cathepsins B, K, L and S.

15

Examples of dipeptide nitrile-based cathepsin S inhibitors have been reported by Novartis application, WO 99/24460, 1999 and related US patent 6,353,017. One of the generic structures is depicted below.

20




It is disclosed that R4 and R5 together represent lower alkylene, optionally interrupted by O, S, or NR6, so as to form a ring with the carbon atom to which they are attached, R3 is lower alkyl (defined as 1-7 carbon atoms branched or unbranched). However, in these documents, specific examples are limited to R4 and R5 being hydrogen, methyl, or joined together form cyclopropyl. No examples of R4 and R5 heterocyclic fusion are described. WO 99/24460 exemplifies larger R4 R5 fused carbocycles such as cyclohexyl but does not provide examples of heterocycles or teach that they will offer any advantage.

30

Furthermore although the description of R3 may generically encompass alkyl P2 side chains it does not exemplify specific structures providing the advantages of the present invention.

- 5 Another class of dipeptide nitrile-based cathepsin S inhibitors is described in US patent 6,492,362. A specific example is claimed in this patent possessing an N-methyl piperidine P1 heterocycle. However, by definition the subject matter encompassed by US 6,492,362 requires a sulfonyl containing P2 side chain as illustrated in the following generic structure.

10



- US patent nos. 6,525,052 and 6,420,364, commonly owned by the assignee of the present application, describe dipeptide nitriles bearing P1 heterocycles, the invention described  
15 herein provides a non-obvious benefit of improved selectivity profile.

Additional peptidyl nitriles have been reported as protease inhibitors. For example, both nitriles and ketoheterocycles are described by B.A. Rowe et al. (US 5,714,471) as protease inhibitors useful in the treatment of neurodegenerative diseases. Peptidyl nitriles  
20 are reported by B. Malcolm et al. (WO 9222570) as inhibitors of picornavirus protease. B.J. Gour-Salin (Can. J. Chem., 1991, 69, 1288) and T.C. Liang (Arch. Biochim. Biophys., 1987, 252, 626) described peptidyl nitriles as inhibitors of papain

- A reversible inhibitor presents a more attractive therapy than irreversible inhibitors.  
25 Even compounds with high specificity for a particular protease can bind non-target

enzymes. An irreversible compound could therefore permanently inactivate a non-target enzyme, increasing the likelihood of toxicity. Furthermore, any toxic effects resulting from inactivation of the target enzyme would be mitigated by reversible inhibitors, and could be easily remedied by modified or lower dosing. Finally, covalent modification of  
5 an enzyme by an irreversible inhibitor could potentially generate an antibody response by acting as a hapten.

A highly selective protease inhibitor also offers a more attractive therapeutic option. In general, selectivity is desired in order to avoid potential toxicities associated with  
10 inhibiting additional targets. Cathepsin L is a closely related family member of cathepsin S. Mice deficient of cathepsin L or possessing nonfunctional cathepsin L, have been shown to demonstrate numerous undesirable phenotypes including brain atrophy (U. Felbor et al., 2002, PNAS USA, 99 (12) 7883) progressive cardiomyopathy (J. Stypmann, et al., 2002, PNAS USA, 99 (9) 6234), impairment of the male reproductive system (W.  
15 W. Wright, et al., 2003, Biology of Reproduction, 68 (2) 680), and severe epidermal hyperplasia (F. Benavides, et al., 2002, American Journal of Pathology, 161 (2) 693).

In light of the above, there is a clear need for compounds which reversibly and selectively inhibit cathepsin S for indications in which these proteases exacerbate disease.

20

### SUMMARY OF THE INVENTION


25 It is therefore an object of this invention to provide compounds as described herein which reversibly and selectively inhibit the cysteine protease cathepsin S. It is a further object of the invention to provide methods for treating diseases and pathological conditions exacerbated by these cathepsin S such as, but not limited, to rheumatoid arthritis, multiple sclerosis and asthma. It is yet a further object of the invention to provide processes for  
30 preparation of the above-mentioned compounds.



# DETAILED DESCRIPTION OF THE INVENTION


The compounds of the invention feature specific P2 side chains 3,3-dimethyl pentyl(I),  
 5 2,2,3,3-tetramethyl butyl(II), and 3,3-dimethyl butyl(III) which substantially improve the  
 selectivity profile of these inhibitors for cathepsin S over its closely related family  
 member cathepsin L.

Accordingly, in one aspect of the invention, there are provided compounds of formulas  
 10 (I), (II) and which are selective for cathepsin S:



15

wherein X in each case is chosen from




20

R1 is chosen from hydrogen or alkyl branched or straight chain alkyl, each carbon atom in the chain is optionally replaced with one to three heteroatoms chosen from O, S, and N-R2 wherein R2 is hydrogen or alkyl;


- 5 and wherein R1 is optionally further substituted by one or more alkoxy, amine, halogen, carbocycle, heteroaryl or heterocycle;

or the pharmaceutically acceptable salts thereof.

- 10 In another embodiment of the invention, there are provided compounds of the formula (I) as described immediately above



- 15 wherein X is chosen from




- R1 is chosen from hydrogen or C1-10 alkyl branched or straight chain C1-10 alkyl, each carbon atom in the chain is optionally replaced with one to three heteroatoms chosen from O, S, and N-R2 wherein R2 is hydrogen or C1-5 alkyl;
- 20

and wherein R1 is optionally further substituted by one or more C-15 alkoxy, amine, heterocycle or halogen.

- 5 One preferred embodiment of R1 includes C1-5 alkyl, preferably C1-3 alkyl, most preferably methyl.


In another preferred embodiment of R1, R1 is chosen from:



10




In a preferred embodiment of the invention, there are provided compounds of the formula (I) according to any of the embodiments described herein-above and wherein the indicated chiral carbon below is the (S) enantiomer which possesses a natural amino acid configuration

15




- 20 In another aspect of the invention, there is provided the following compounds which are selective for cathepsin S:

;



or the pharmaceutically acceptable salts thereof.


- 10 In another embodiment of the invention, there is provided the following compound which is selective for cathepsin S:




wherein the indicated chiral carbon below is the (S) enantiomer which possesses a natural  
 5 amino acid configuration;  
 or the pharmaceutically acceptable salts thereof.

In a second aspect of the invention, there is provided the following compound of the  
 formula (III) which is selective for cathepsin S:



10



;



;



5

or the pharmaceutically acceptable salts thereof.

- 10 Unless otherwise noted, any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S configuration unless otherwise specified, or a
- 15 combination of configurations.

In preferred compounds of the invention, the P2 chiral carbon is the (S) enantiomer which possesses a natural amino acid configuration.

Some of the compounds of the invention can exist in more than one tautomeric form.  
The invention includes all such tautomers.

- 5 It shall be understood by one of ordinary skill in the art that all compounds of the invention are those which are chemically stable.

The invention includes pharmaceutically acceptable derivatives of compounds of the invention. A "pharmaceutically acceptable derivative" refers to any pharmaceutically  
10 acceptable acid, salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof.

- 15 In addition, the compounds of this invention include prodrugs. Prodrugs include those compounds that, upon simple transformation, are modified to produce the compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction which occur enzymatically, metabolically or otherwise. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed  
20 into a compound of the invention, thereby imparting the desired pharmacological effect.

Of particular importance according to the invention are compounds of formulas (I), (II) or (III), wherein X and R1 have the meaning indicated, for use as pharmaceutical compositions with anti-cathepsin S activity.

25

The invention also relates to the use of a compound of formulas (I), (II) or (III), wherein X and R1 have the meaning indicated, for preparing a pharmaceutical composition for the treatment and/or prevention of a disease or condition related to capthepsin S.

- 30 The invention also relates to pharmaceutical preparations, containing as active substance one or more compounds of formulas (I), (II) or (III), wherein X and R1 have the

meanings indicated, or the pharmaceutically acceptable derivatives thereof, optionally combined with conventional excipients and/or carriers.

In order that the invention herein described may be more fully understood, the following  
5 detailed description is set forth. As used herein, the following abbreviations are used:

BOC or t-BOC is tertiary-butoxycarbonyl;

t-Bu is tertiary-butyl;

DMF is dimethylformamide;

10 EtOAc is ethyl acetate;

THF is tetrahydrofuran;

NMM is 4-methyl morpholine

CH<sub>2</sub>Cl<sub>2</sub> is dichloromethane;

MgSO<sub>4</sub> is magnesium sulfate;

15 Na<sub>2</sub>SO<sub>4</sub> is sodium sulfate;

Ar is argon;

EDC is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and

HOBT is 1-hydroxybenzotriazole.

20

Also, as used herein, each of the following terms, used alone or in conjunction with other terms, are defined as follows (except where noted to the contrary):

The term "alkyl" refers to a saturated aliphatic radical containing from one to ten carbon  
25 atoms or a mono- or polyunsaturated aliphatic hydrocarbon radical containing from two to twelve carbon atoms. The mono- or polyunsaturated aliphatic hydrocarbon radical containing at least one double or triple bond, respectively. "Alkyl" refers to both branched and unbranched alkyl groups. Examples of "alkyl" include alkyl groups which are straight chain alkyl groups containing from one to eight carbon atoms and branched  
30 alkyl groups containing from three to eight carbon atoms. Other examples include lower alkyl groups which are straight chain alkyl groups containing from one to six carbon



atoms and branched alkyl groups containing from three to six carbon atoms. It should be understood that any combination term using an "alk" or "alkyl" prefix refers to analogs according to the above definition of "alkyl". For example, terms such as "alkoxy", "alkythio" refer to alkyl groups linked to a second group via an oxygen or sulfur atom.

- 5 "Alkanoyl" refers to an alkyl group linked to a carbonyl group (C=O). Each alkyl or alkyl analog described herein shall be understood to be optionally partially or fully halogenated.

- Carbocycle refers to "aryl" being aromatic or partially saturated, or a nonaromatic cycloalkyl.

- The term "cycloalkyl" refers to the cyclic analog of an alkyl group, as defined above. Examples of cycloalkyl groups are saturated or unsaturated nonaromatic cycloalkyl groups containing from three to eight carbon atoms, and other examples include cycloalkyl groups having three to six carbon atoms. Each cycloalkyl described herein shall be understood to be optionally partially or fully halogenated.

The term "aryl" refers to phenyl and naphthyl.

- The term "halogen" refers to a halogen radical selected from fluoro, chloro, bromo or iodo. Representative halogen groups of the invention are fluoro, chloro and bromo.

- The term "heteroaryl" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocycle radical. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Examples of "heteroaryl" include radicals such as furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indoliziny, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinoliziny, quinolinyl,

isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl,

The term "heterocycle" refers to a stable 4-8 membered (but preferably, 5 or 6  
5 membered) monocyclic or 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated, and is non-aromatic. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Examples of "heterocycle" include radicals such as pyrrolinyl,  
10 pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, azetidiny, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranly, hexahydropyrimidinyl, hexahydropyridazinyl, 1,4,5,6-tetrahydropyrimidin-2-ylamine, dihydro-oxazolyl, 1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-1,1-dioxide, isothiazolidinyl-1,1-dioxide and imidazolidinyl-2,4-  
15 dione.

The terms "heterocycle", "heteroaryl" or "aryl", when associated with another moiety, unless otherwise specified shall have the same meaning as given above. For example, "aroyl" refers to phenyl or naphthyl linked to a carbonyl group (C=O).

20

Each aryl or heteroaryl unless otherwise specified includes it's partially or fully hydrogenated derivative. For example, quinolinyl may include decahydroquinolinyl and tetrahydroquinolinyl, naphthyl may include it's hydrogenated derivatives such as tetrahydronaphthyl. Other partially or fully hydrogenated derivatives of the aryl and  
25 heteroaryl compounds described herein will be apparent to one of ordinary skill in the art.

The term "amine" shall be understood to mean an -NH<sub>2</sub> group wherein each hydrogen atom may be replaced by alkyl, carbocycle, carbocyclealkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl such that the amine nitrogen may be mono- or di-  
30 substituted by said groups.

As used herein above and throughout this application, "nitrogen" and "sulfur" include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating preferred embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.

The examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds. Starting materials used in the scheme below are either commercially available or easily prepared from commercially available materials by those skilled in the art.

### GENERAL SYNTHETIC METHODS

15

The invention also provides processes of making the present compounds described herein. Compounds of the invention may be prepared by methods described below, those found US patent nos. 6,420,364 and 6,525,052 each incorporated herein by reference in their entirety, and by methods known to those of ordinary skill in the art.

20

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.

25

The examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds without undue experimentation. Starting materials used in the scheme below are either commercially available or easily prepared from commercially available materials by those skilled in the art.

30


**SYNTHETIC EXAMPLES**

5

Examples 1-4 illustrate the synthesis of P2 amino acid intermediates used in the synthesis of novel compounds of formula (I).

**Example 1: Synthesis of 2-*tert*-butoxycarbonylamino-4,4,5,5-trimethyl-hexanoic acid**

10



Lithium diisopropylamide (LDA) (1.5 M solution in cyclohexane/THF/ethylbenzene) (106 mL, 160 mmol, 1.15 equiv) was syringed into a 1000 mL round-bottom flask under a blanket of Ar. Dry THF (150 mL) was added and the mixture was cooled to  $-78^\circ\text{C}$

with a dry-ice/acetone bath. 3,3-Dimethyl-butanoic acid ethyl ester (20 g, 23.3 mL, 139 mmol, 1.0 equiv) was added dropwise from a syringe over a 10 min period followed by stirring at -78 °C for 1 h. Methyl iodide (9.5 mL, 152 mmol, 1.1 equiv) was added dropwise from a syringe over a 10 min period and the creamy mixture was stirred for 1 h at -78 °C, resulting in a very thick mixture. The dry-ice bath was removed and replaced with an ice bath at 0 °C. Another 150 mL of dry THF was added followed by another addition of LDA (106 mL, 160 mmol, 1.15 equiv). The resulting mixture was stirred for 10 min and then the flask was re-immersed in a dry-ice/acetone bath. Stirring was continued for another 50 min and then methyl iodide was added dropwise (9.5 mL, 152 mmol, 1.1 equiv) and the dry-ice/acetone bath was removed and the resulting mixture was stirred at ambient temperature for 14 h. The reaction mixture was quenched with 3 mL of concentrated HCl and 2 N HCl was added until the pH was adjusted to <1. The mixture was further diluted with 150 mL water and 500 mL Et<sub>2</sub>O. The layers were separated and the organic layer was washed with 1 x 100 mL 2 N HCl, 1 x 100 mL saturated NaHCO<sub>3</sub>, and 1 x 200 mL brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated *in vacuo* to provide 2,2,3,3-trimethylbutanoic acid ethyl ester as an orange oil mixed with ethyl benzene, 19.8 g of which (80% yield) was product by NMR. The mixture was used without further purification.

A 500 mL round-bottom flask equipped with a stir bar was flushed with Ar and charged with 50 mL dry THF and a 1 M solution of LiAlH<sub>4</sub> in Et<sub>2</sub>O (70.6 mL, 70.6 mmol, 0.625 equiv). The solution was cooled to 0 °C with an ice bath and the above ethyl ester (19.5 g, 113 mmol, 1.0 equiv) (approximately a 50% solution in ethylbenzene) was added dropwise at such a rate that the solution did not reflux (required 50 min). After addition of the ester, the reaction was stirred at 0 °C for 2 h and then at ambient temperature for 14 h. The reaction solution was re-cooled to 0 °C and carefully quenched by addition of EtOAc. 1 N NaOH was added until a granular precipitate formed (7.5 mL). The mixture was filtered on a pad of diatomaceous earth which was then washed 3 x 100 mL Et<sub>2</sub>O. The organics were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solution was decanted and concentrated *in vacuo* to yield 2,2,3,3-tetramethyl-butanol as a nearly colorless oil (12.9g,

88% crude yield, in a mixture with ethylbenzene). The crude product was used without further purification.

A 1000 mL round-bottom-flask was equipped with a stir bar, flushed with Ar and  
5 charged with 500 mL dry  $\text{CH}_2\text{Cl}_2$  and 2,2,3,3-tetramethyl-butanol (12.9 g, 99.2 mmol, 1.0 equiv). Pyridinium chlorochromate (PCC) (20.7 g, 96 mmol) was added portionwise over 5 min. The reaction mixture turned dark rapidly and was stirred at room temperature for 3 h. The reaction solvent was then decanted, washed 1 N HCl (1 x 250 mL), and concentrated on a rotary evaporator. The resulting pasty residue was stirred  
10 with hexanes (300 mL) for 10 min then filtered. The filtrate was dried with  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated to provide 8.3 g (65% yield) of the desired 2,2,3,3-tetramethyl-butanol which was used without further purification.

A dry 250 mL round-bottom flask was equipped with a stir bar and flushed with Ar. Dry  
15 THF was added (40 mL) followed by addition of a 1.0 M solution of KO-*t*-Bu (37.5 mL, 37.5 mmol, 1.2 equiv). The solution was cooled to  $-78^\circ\text{C}$  in a dry-ice/acetone bath. Methyl isocynoacetate (3.12 mL, 34.4 mmol, 1.0 equiv) was added dropwise over a 10 min period. The resulting mixture was stirred an additional 5 min followed by addition of 2,2,3,3-tetramethyl-butanol (4.0 g, 31.2 mmol, 1.0 equiv) via syringe. The cold-bath  
20 was removed and resulting mixture was stirred at room temperature for 1 h. The reaction mixture was diluted by addition of a mixture of 125 mL  $\text{Et}_2\text{O}$ , 20 g ice and 2 mL AcOH. After the ice melted, 50 mL of water was added and the layers were mixed and separated. The organic layer was washed with 1 x 50 mL sat.  $\text{NaHCO}_3$  and dried over  $\text{Na}_2\text{SO}_4$ . The organic layer was decanted and concentrated. The crude enamide was purified by flash  
25 chromatography on silica gel using  $\text{CH}_2\text{Cl}_2$  to 4% MeOH in  $\text{CH}_2\text{Cl}_2$  to provide 2-formylamino-4,4,5,5-tetramethyl-hex-2-enoic acid ethyl ester as a thick oil (5.26 g, 74%);  $m/z$  calculated for  $\text{C}_{12}\text{H}_{21}\text{NO}_3$  227.3, found 228.3 ( $\text{M}+\text{H}$ ) $^+$ .


The above methyl ester (5.26 g, 23.2 mmol, 1.0 equiv) was dissolved in 35 mL of MeOH  
30 in a Parr bottle followed by addition of  $\text{PtO}_2$  (1 g, 4.4 mmol, 0.2 equiv). The mixture was shaken on a Parr hydrogenation apparatus for 4 days at which time MS showed

consumption of the starting material. The liquid was carefully decanted and the Pt was washed three times with 20 mL MeOH followed each time by decantation, being careful not to allow the Pt to dry (if allowed to dry, the Pt may ignite). The MeOH solutions containing the reduction product were combined and concentrated to a thick oil that was  
5 suspended in 25 mL of 6 N HCl and the mixture was refluxed for 4 h during which time 5 mL of concentrated HCl was added at the end of each of the first 3 h.. The mixture was cooled and the water and excess HCl were removed *in vacuo* at a bath temperature of 70 °C. After about 50% concentration, a flaky crystalline solid formed. The mixture was cooled to 0 °C and the precipitate was collected by filtration. The filtrate was again  
10 concentrated by about 50% and cooled again to 0 °C to provide a second crop of crystals. The crystals were combined and dried under high vacuum to provide 2-amino-4,4,5,5-tetramethyl-hexanoic acid hydrochloride as an off-white crystalline solid (1.40 g, 27% yield); *m/z* calculated for C<sub>10</sub>H<sub>21</sub>NO<sub>2</sub> 187.3, found 188.3 (M+H)<sup>+</sup>.

15 The above amino acid salt (1.40 g, 6.26 mmol, 1.0 equiv) was dissolved in 100 mL of 50/50 dioxane/4 N NaOH. The solution was cooled to 0 °C and Boc anhydride (2.05 g, 9.39 mmol, 1.5 equiv) was added. The cold-bath was removed and the reaction stirred at ambient temperature for 16 h. The pH was carefully adjusted to 2 with concentrated HCl, and the product was extracted with 3 x 100 mL CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were  
20 combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solution was decanted and concentrated using 100 mL of hexane as a chaser to provide a thick glass, which was triturated with 100 mL of hexane. After vigorous stirring for 4 h, a waxy solid resulted which was filtered and dried in air to provide the title compound (1.21 g, 67% yield); *m/z* calculated for C<sub>15</sub>H<sub>29</sub>NO<sub>4</sub> 287.4, found 286.3 (M-H)<sup>-</sup>.

25

**Example 2: Synthesis of 2-*tert*-butoxycarbonylamino-5,5-dimethyl-heptanoic acid**



3,3-Dimethyl-pent-4-enoic acid methyl ester (20.0 mL, 126 mmol, 1.00 eq) was cautiously introduced via pipet into a 2 L flask containing a suspension of  $\text{LiAlH}_4$  (3.63 g, 96 mmol, 0.76 eq) in 500 mL of anhydrous diethyl ether cooled by an ice water bath.

5 The reaction mixture was allowed to warm to room temperature overnight while stirring, then quenched by slow addition of a saturated sodium potassium tartrate solution (150 mL). The mixture was diluted with ether (200 mL), and the organic layer was separated, dried ( $\text{MgSO}_4$ ), and concentrated to provide 3,3-dimethyl-pent-4-en-1-ol as a colorless liquid (11.0 g, 76% yield). This material was used without further purification;  $^1\text{H}$  NMR

10 ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  1.00 (s, 6 H), 1.58 (t,  $J = 7.3$  Hz, 2H), 2.07 (s, 1H), 3.59 (t,  $J = 7.3$  Hz, 2H), 4.89-4.94 (m, 2 H), 5.80 (dd,  $J = 17.3, 14.1$ , 1 H).

Anhydrous DMSO (17.1 mL, 241 mmol, 2.5 eq) was added dropwise to a solution of oxalyl chloride (10.5 mL, 120 mmol, 1.25 eq) in dry  $\text{CH}_2\text{Cl}_2$  (400 mL) cooled with a dry

15 ice/acetone bath. This solution was stirred 45 min, then 3,3-dimethyl-pent-4-en-1-ol (11.0 g, 96.3 mmol, 1.00 eq) was added via cannula as a solution in  $\text{CH}_2\text{Cl}_2$  (50 mL). The resulting solution was stirred at  $-78^\circ\text{C}$  for 2 h. Triethylamine (54 mL, 385 mmol, 4.0 eq) was added and the cooling bath was removed. The reaction was warmed to room



temperature and stirred an additional 1.5 h. The reaction mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with saturated Na<sub>2</sub>CO<sub>3</sub> solution, followed by 1 N HCl (500 mL). The organic phase was dried (MgSO<sub>4</sub>), concentrated, and the resulting residue was taken up in petroleum ether (100 mL) and filtered through a short plug of silica gel to  
5 provide the desired 3,3-dimethyl-pent-4-en-1-al (5.80 g, 54% yield) as a colorless liquid; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.14(s, 6 H), 2.33(d, *J* = 3.1 Hz, 2H), 4.98-5.03 (m, 2 H), 5.92 (dd, *J* = 17.0, 6.0, 1 H), 9.71 (t, *J* = 3.1 Hz, 1H).


A solution of N-(benzyloxy carbonyl)-α-phosphonoglycine trimethyl ester (15.0 g, 45.3,  
10 1.00 eq), 3,3-dimethyl-4-pent-4-en-1-al (5.64 g, 50.3 mmol, 1.11 eq), and DBU (6.8 mL, 45.5 mmol, 1.0 eq) in dry THF (150 mL) was stirred at room temperature for 16 h. The reaction mixture was diluted with ether (200 mL), washed with water (2 x 100 mL), then brine (100 mL). The organic layer was dried (MgSO<sub>4</sub>), and concentrated. The resulting residue was chromatographed over silica gel using a gradient of ethyl acetate in hexanes  
15 as the eluant to provide the desired enamide as a yellow oil which solidified upon standing (8.60 g, 60% yield); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.03 (s, 6 H), 2.21 (d, *J* = 7.3 Hz, 2H), 3.75 (s, 3H), 4.94-4.98 (m, 2 H), 5.14 (s, 2H), 5.78 (dd, *J* = 10.9, 10.0 Hz, 1H), 6.10-6.20 (m, 1H), 6.65 (t, *J* = 7.3 Hz), 7.33-7.38 (m, 5H).

A suspension of 10% Pd/C catalyst (1.25 g), (Z)-2-benzyloxycarbonylamino-5,5-dimethyl-hepta-2,6-dienoic acid methyl ester (8.60 g, 27 mmol, 1.0 eq), and Boc anhydride (6.48 g, 29.7 mmol, 1.1 eq) in methanol (100 mL) was shaken on a Parr hydrogenation apparatus under 40 psi of hydrogen for 3 days. The reaction mixture was filtered through a pad of diatomaceous earth and concentrated to provide tert-  
25 butoxycarbonylamino-5,5-dimethyl-heptanoic acid methyl ester as a white solid (6.10 g, 79% yield); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 0.77 (t, *J* = 15.1 Hz, 3 H), 0.80 (s, 6 H), 1.1-1.3 (m, 4H), 1.42 (s, 9H), 1.55-1.65 (m, 1H), 1.7-1.8 (m, 1 H), 3.74 (s, 3H), 4.20-4.35 (m, 1H), 4.95-5.05 m, 1H).

A suspension of the above methyl ester (6.10 g, 21.2 mmol, 1.00 eq) and lithium hydroxide mono hydrate (6.2 g, 148 mmol, 6.98 eq) in tetrahydrofuran (20 mL),

methanol (5 mL), and water (5 mL) was stirred at room temperature for 5 h. The reaction mixture was diluted with diethyl ether (100 mL) and washed with 1N HCl (2 x 50 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated to provide the title compound (5.05 g, 87% yield) as a white solid; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 0.74-0.82 (m, 9 H), 1.10-1.28 (m, 4H), 1.45 (s, 9H), 1.52-1.63 (m, 1H), 1.75-1.90 (m, 1H), 4.20-4.30 (m, 1H), 4.94-5.02 (m, 1H).

**Example 3: Synthesis of (S)-2-*tert*-butoxycarbonylamino-5,5-dimethyl-heptanoic acid**




R,R-DIPAMP cyclooctadiene Rh(I) tetrfluoroborate (190 mg, 0.25 mmol, 0.04 eq) was added to a solution of (Z)-2-benzyloxycarbonylamino-5,5-dimethyl-hepta-2,6-dienoic acid methyl ester (2.00 g, 6.30 mmol, 1.00 eq) in dry methanol (20 mL) in a Paar hydrogenation flask. The reaction vessel was evacuated and flushed with a hydrogen atmosphere three times, then vigorously shaken under 50 psi of hydrogen overnight. The reaction mixture was concentrated *in vacuo* then filtered through a plug of silica gel using a gradient of ethyl acetate in hexanes as the eluant to provide (S)-2-benzyloxycarbonylamino-5,5-dimethyl-heptanoic acid methyl ester as a yellow oil (1.63 g, 81% yield); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 0.74-0.90 (m, 9 H), 1.10-1.30 (m, 4H), 1.58-1.70 (m, 1H), 1.75-1.90 (m, 1H), 3.75 (s, 3 H), 4.30-4.40 (m, 1H), 5.14 (s, 2H), 5.24-5.33 (m, 1H), 7.30-7.37 (m, 5H); [α]<sub>D</sub><sup>20</sup> = + 15.57 c = 2.00, CHCl<sub>3</sub>.

10% Pd/C catalyst (160 mg) was added to a solution of the above Cbz-protected amino acid (1.63 g, 5.07 mmol, 1.00 eq), and Boc anhydride (1.16 g, 5.32 mmol, 1.05 eq), in methanol (25 mL) in a Paar reaction vessel. The reaction mixture was shaken under 50 psi of hydrogen overnight. Filtration of the reaction mixture through a pad of  
5 diatomaceous earth and concentration of the resulting filtrate provided 1.33 g (91% yield) of the Boc protected intermediate. This material was used without further purification.

A suspension of the above Boc protected intermediate (1.33 g, 4.63 mmol, 1.00 eq) and lithium hydroxide mono hydrate (1.36 g, 32.4 mmol, 7.00 eq) in tetrahydrofuran (5 mL),  
10 methanol (2 mL), and water (2 mL) was stirred at room temperature for 5 h. The reaction mixture was diluted with diethyl ether (100 mL) and washed with 1 N HCl (2 x 50 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated to provide the title compound (991 mg, 78% yield) as a white solid. <sup>1</sup>H NMR matches that of the racemic product (Example 2).

15

**Example 4: Synthesis of (R)-2-*tert*-butoxycarbonylamino-5,5-dimethyl-heptanoic acid**




20

This compound was prepared via an analogous method to its enantiomer (Example 3) but substituting R,R DuPhos rhodium triflate as a catalyst for the asymmetric hydrogenation reaction. <sup>1</sup>H NMR matches that of the racemic product (Example 2).

25

Examples 5-8 illustrate the synthesis of novel compounds of the invention described herein-above.

**Example 5: Synthesis of morpholine-4-carboxylic acid [(S)-1-(4-cyano-1-methyl-piperidine-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-amide**



Isobutyl chloroformate (0.47 mL, 3.62 mmol, 1.00 eq) was added dropwise to a solution  
 10 of (S)-2-*tert*-Butoxycarbonylamino-5,5-dimethyl-heptanoic acid (Example 3) (991 mg,  
 3.62 mmol, 1.00 eq), and 4-methyl morpholine (1.2 mL, 10.9 mmol, 3.00 eq) in 10.0 mL  
 of anhydrous THF, cooled with an ice water bath. The reaction mixture was warmed to  
 room temperature and stirred for 30 min. A solution of N-methyl piperidine amino nitrile  
 (500 mg, 3.60, 0.99 eq) in dry THF (5.0 mL) was then added and the stirring was  
 15 continued overnight at room temperature. The reaction mixture was then concentrated,  
 taken up in ethyl acetate (50 mL), and washed with saturated Na<sub>2</sub>CO<sub>3</sub> (2 x 25 mL). The  
 organic phase was dried (MgSO<sub>4</sub>) and concentrated. The resulting residue was  
 chromatographed over silica gel using a gradient of methanol in dichloromethane as the

eluant to provide 415 mg (29% yield) of the desired [(S)-1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-carbamic acid *tert*-butyl ester; *m/z* calculated for  $C_{21}H_{38}N_4O_3$  394.5, found 395.4 ( $M+H$ )<sup>+</sup>.


- 5 The above *tert*-butyl ester (415 mg, 1.05 mmol, 1.00 eq) was treated with 4.0 N HCl in dioxane (10 mL) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, resuspended in chloroform (50 mL) and concentrated to provide the desired (S)-2-amino-5,5-dimethyl-heptanoic acid (4-cyano-1-methyl-piperidine-4-yl)-amide hydrochloride salt (307 mg, 78% yield). *m/z* calculated for  
10  $C_{16}H_{30}N_4O$  294.4, found 295.1 ( $M+H$ )<sup>+</sup>.

- A suspension of the above hydrochloride salt (301 mg, 0.82 mmol, 1.00 eq), morpholine carbonyl chloride (0.10 mL, 0.82 mmol, 1.00 eq), and 4-methyl morpholine (0.27 mL, 2.4 mmol, 2.93 eq) in dry THF (5.0 mL) was stirred at room temperature overnight. The  
15 reaction mixture was then concentrated, taken up in ethyl acetate (50 mL), and washed with saturated  $Na_2CO_3$  (2 x 25 mL). The organic phase was dried ( $MgSO_4$ ) and concentrated. The resulting residue was chromatographed over silica gel using a gradient of methanol in dichloromethane as the eluant to provide 115 mg (34% yield) of the title compound as a white solid; *m/z* calculated for  $C_{21}H_{37}N_5O_3$  407.6, found 408.6 ( $M+H$ )<sup>+</sup>.  
20 Chiral HPLC indicates > 97% ee ( Chirobiotic T column from Advanced Separation Technologies)

The following compounds were prepared by procedures analogous to the procedure described in the above example:


25

**Morpholine-4-carboxylic acid [1-(4-cyano-1-propyl-piperidine-4-ylcarbamoyl)-3,3,4,4-tetramethyl-pentyl]-amide**




$m/z$  calculated for  $C_{24}H_{43}N_5O_3$  449.6, found 450.6 ( $M+H$ )<sup>+</sup>;

5 **Morpholine-4-carboxylic acid [1-(4-cyano-1-propyl-piperidine-4-ylcarbamoyl)-4,4-dimethyl-pentyl]-amide**




The requisite P2 amino acid intermediate, 2-*tert*-Butoxycarbonylamino-5,5-dimethyl-hexanoic acid, was prepared by an analogous procedure to that described for 2-*tert*-butoxycarbonylamino-5,5-dimethyl-heptanoic acid (Example 2) substituting the commercially available 3,3-dimethyl butan-1-al for intermediate 3,3-dimethyl-pent-4-en-1-ol;  $m/z$  calculated for  $C_{22}H_{39}N_5O_3$  421.6, found 422.9 ( $M+H$ )<sup>+</sup>;

15 **Morpholine-4-carboxylic acid [1-(4-cyano-1-propyl-piperidine-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-amide**



$m/z$  calculated for  $C_{23}H_{41}N_5O_3$  435.6, found 436.5 ( $M+H$ )<sup>+</sup>.

5 **Example 6: Synthesis of morpholine-4-carboxylic acid [(S)-1-(4-cyano-1-methyl-piperidine-4-ylcarbonyl)-4,4-dimethyl-hexyl]-amide (6)**



10

10% Pd/C (1.5 g) was added to a solution of Cbz protected amino acid ester (see Example 2) (27 g, 84 mmol) and ethyl acetate (135 mL). The atmosphere of the reaction vessel was evacuated and filled with 50 psi of hydrogen. The reaction mixture was

shaken vigorously for 16 h then filtered through a large pad of diatomaceous earth. The filtrate was concentrated on a rotary evaporator to provide the desired amine intermediate as a light yellow oil (15.7 g, 100% yield);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  0.74-0.79 (m, 9 H), 1.14-1.23 (m, 4H), 1.40-1.80 (m, 2H), 3.37 (t,  $J=3.6$  Hz, 1H), 3.69 (s, 3 H).

5

To a solution of the above amine intermediate (16.0 g, 85.4 mmol, 1.00 eq) in dry THF (300 mL) was added 4-methyl morpholine (10.4 mL, 94 mmol, 1.10 eq), followed by dropwise addition of morpholine carbonyl chloride (10.0 mL, 85.7 mmol, 1.00 eq). The reaction mixture was stirred at room temperature for 5 h, then diluted with diethyl ether (400 mL) and washed with 1N HCl (2 x 500 mL). The organic phase was dried ( $\text{MgSO}_4$ ) and concentrated to provide the desired (S)-5,5-dimethyl-2-[(morpholine-4-carbonyl)-amino]-heptanoic acid methyl ester as a white solid (22.5 g, 88% yield);  $m/z$  calculated for  $\text{C}_{15}\text{H}_{28}\text{N}_2\text{O}_4$  300.4, found 301.1 ( $\text{M}+\text{H}$ ) $^+$ .

15 The above methyl ester (12.9 g, 42.9, 1.00 eq), was dissolved in methanol (60 mL) then treated with 1N LiOH (180 mL, 4.20 eq). The reaction mixture was stirred at room temperature for 2 h, then washed with diethyl ether (200 mL). The aqueous phase was then acidified to pH < 1 with concentrated HCl and extracted with diethyl ether (2 x 200 mL). The organic phases were combined, dried ( $\text{MgSO}_4$ ) and concentrated to provide the  
20 desired carboxylic acid (9.0 g, 73% yield);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  0.79 (t,  $J=7.5$  Hz, 3 H), 0.82 (s, 6H), 1.60-1.73 (m, 1H), 1.80-1.95 (m, 1H) 3.37-3.42 (m, 4H), 3.69-3.72 (m, 4 H), 4.30-4.40 (m, 1H), 4.96-5.04 (m, 1H).


A mixture of the above carboxylic acid (4.5 g, 15.7 mmol, 1.08 eq), HOBt (2.93 g, 21.7  
25 mmol, 1.5 eq), and EDC (3.06 g, 16.0 mmol, 1.10 eq) in dry dichloromethane was stirred at 0°C for 35 min. A solution of 4-amino-1-methyl-piperidine-4-carbonitrile (2.02 g, 14.5 mmol, 1.00 eq) in dichloromethane (10 mL) was added in one portion, and the reaction mixture was allowed to warm to room temperature overnight. Solvent was removed *in vacuo* and the crude product was dissolved in a minimum amount of  
30 methanol and precipitated with water to provide the title compound as a white solid (2.70 g, 42% yield);  $m/z$  calculated for  $\text{C}_{21}\text{H}_{37}\text{N}_5\text{O}_3$  407.6, found 408.6 ( $\text{M}+\text{H}$ ) $^+$ ; chiral HPLC



analysis indicated > 99% ee ( Chirobiotic T column from Advanced Separation Technologies).

The following compound was prepared by procedures analogous to the procedure  
5 described in the above example:

**Morpholine-4-carboxylic acid [(R)-1-(4-cyano-1-methyl-piperidine-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-amide**




10

m/z calculated for  $C_{21}H_{37}N_5O_3$  407.6, found 408.6  $(M+H)^+$ ; chiral HPLC indicates > 99% ee (Chirobiotic T column from Advanced Separation Technologies).

15

**Example 7: Synthesis of 5,5-dimethyl-2-(2-oxo-2H-benzo[e][1,3]oxazin-4-ylamino)-heptanoic acid (4-cyano-1-propyl-piperidin-4-yl)-amide**




20

A suspension of 4-chloro-benzo[e][1,3]oxazin-2-one (620 mg, 3.41 mmol, 2.0 eq), 2-amino-5,5-dimethyl-heptanoic acid (4-cyano-1-propyl-piperidin-4-yl)-amide (675 mg, 1.71 mmol, 1.00 eq), and 4-methylmorpholine (NMM) (0.56 mL, 5.09 mmol, 3.00 eq) in acetonitrile (9.0 mL) was stirred at room temperature overnight. The reaction mixture  
5 was then concentrated, resuspended in ethyl acetate (50 mL) and washed with saturated  $\text{Na}_2\text{CO}_3$  solution. The organic phase was dried ( $\text{MgSO}_4$ ) and concentrated and the resulting residue was chromatographed over silica gel using a gradient of methanol in dichloromethane as the eluant to provide 124 mg (16% yield) of the title compound;  $m/z$  calculated for  $\text{C}_{26}\text{H}_{37}\text{N}_5\text{O}_3$  467.6, found 468.4 ( $\text{M}+\text{H}$ )<sup>+</sup>.

10

The following compounds were prepared by procedures analogous to the procedure described in the above example:


**5,5-Dimethyl-2-(2-oxo-2*H*-benzo[e][1,3]oxazin-4-ylamino)-heptanoic acid (4-cyano-1-  
15 1-(3-morpholin-4-yl-propyl)-piperidin-4-yl)-amide**



$m/z$  calculated for  $\text{C}_{30}\text{H}_{44}\text{N}_6\text{O}_4$  552.7, found 553.9 ( $\text{M}+\text{H}$ )<sup>+</sup>;


20

**5,5-Dimethyl-2-(2-oxo-2*H*-benzo[e][1,3]oxazin-4-ylamino)-hexanoic acid (4-cyano-1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl)-amide**



m/z calculated for  $C_{28}H_{40}N_6O_4$  524.7, found 525.5 (M+H)<sup>+</sup>;


- 5 **5,5-Dimethyl-2-(2-oxo-2H-benzo[e][1,3]oxazin-4-ylamino)-hexanoic acid {4-cyano-1-[2-(2-methoxy-ethoxy)-ethyl]-piperidin-4-yl}-amide**



- 10 The title compound was prepared by a modification of method 3; m/z calculated for  $C_{27}H_{39}N_5O_5$  513.6, found 514.5 (M+H)<sup>+</sup>;


**5,5-Dimethyl-2-(2-oxo-2H-benzo[e][1,3]oxazin-4-ylamino)-hexanoic acid (4-cyano-1-methyl-piperidin-4-yl)-amide**

15



$m/z$  calculated for  $C_{23}H_{31}N_5O_3$  425, found 426  $(M+H)^+$ .


5 **Example 8: Synthesis of 2-(7-fluoro-2-oxo-2H-benzo[e][1,3]oxazin-4-ylamino)-5,5-dimethyl-heptanoic acid (4-cyano-1-propyl-piperidin-4-yl)-amide**



- 10 2-Chloro-1-methyl pyridinium iodide (365 mg, 1.43 mmol, 1.00 eq) was added to a suspension of 7-fluoro-4-thioxo-3,4-dihydro-benzo[e][1,3]oxazin-2-one (280 mg, 1.42 mmol, 1.00 eq), 2-amino-5,5-dimethyl-heptanoic acid (4-cyano-1-propyl-piperidin-4-yl)-amide (627 mg, 1.42 mmol, 1.00 eq), and N,N-diisopropyl ethylamine (1.00 mL, 5.74 mmol, 4.04 eq) in THF (10.0 mL). The reaction mixture was stirred at room temperature
- 15 overnight, then concentrated, resuspended in ethyl acetate (50 mL) and washed with saturated  $Na_2CO_3$  solution. The organic phase was dried ( $MgSO_4$ ) and concentrated and the resulting residue was chromatographed over silica gel using a gradient of methanol in dichloromethane as the eluant to provide 324 mg (47% yield) of the title compound;  $m/z$  calculated for  $C_{26}H_{36}F N_5O_3$  485.6, found 486.5  $(M+H)^+$ .


The following compounds were prepared by procedures analogous to the procedure described in the above example:

- 2-(7-Fluoro-2-oxo-2*H*-benzo[e][1,3]oxazin-4-ylamino)-5,5-dimethyl-hexanoic acid  
 5 {4-cyano-1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl}-amide



m/z calculated for  $C_{28}H_{39}F N_6O_4$  542.6, found 543.5 (M+H)<sup>+</sup>;

- 10 2-(7-Fluoro-2-oxo-2*H*-benzo[e][1,3]oxazin-4-ylamino)-5,5-dimethyl-hexanoic acid  
 {4-cyano-1-[2-(2-methoxy-ethoxy)-ethyl]-piperidin-4-yl}-amide



m/z calculated for  $C_{27}H_{38}F N_5O_5$  531.6, found 532.4 (M+H)<sup>+</sup>.

15

### METHODS OF THERAPEUTIC USE

The compounds of the invention are useful in inhibiting the activity of cathepsin S. In doing so, these compounds are useful in blocking disease processes mediated by these cysteine proteases.

5 Compounds of this invention effectively block degradation of the invariant chain to CLIP by cathepsin S, and thus inhibit antigen presentation and antigen-specific immune responses. Control of antigen specific immune responses is an attractive means for treating autoimmune diseases and other undesirable T-cell mediated immune responses. Thus, there is provided methods of treatment using the compounds of this invention for  
10 such conditions. These encompass autoimmune diseases and other diseases involving inappropriate antigen specific immune responses including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, Grave's disease, myasthenia gravis, scleroderma, glomerulonephritis, dermatitis including contact and atopic  
15 dermatitis, insulin-dependent diabetes mellitus, endometriosis and asthma including allergic asthma. The compounds of the invention can also be used to treat other disorders associated with extracellular proteolysis such as Alzheimer's disease and atherosclerosis. The compounds of the invention can also be used to treat other disorders associated with inappropriate autoimmune responses, T-cell mediated immune responses, or extracellular  
20 proteolysis mediated by cathepsin S, unrelated to those listed above or discussed in the Background of the Invention. Therefore, the invention also provides methods of modulating an autoimmune disease comprising administering to a patient in need of such treatment a pharmaceutically effect amount of a compound according to the invention.

25 For therapeutic use, the compounds of the invention may be administered in any conventional dosage form in any conventional manner. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation. The preferred  
30 modes of administration are oral and intravenous.

The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. Advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds may then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 15%, but more preferably at least about 20%, of a compound of the invention (w/w) or a combination thereof. Alternatively, the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.

As mentioned above, dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G. Popovich, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 10-1000 mg/dose for a 70 kg patient. Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance,

specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

5

## ASSESSMENT OF BIOLOGICAL PROPERTIES

### Expression and Purification of recombinant human Cathepsin S

#### Cloning of human cathepsin S:

10 U937 RNA was subjected to reverse transcriptase / polymerase chain reaction with primer A (5'cacaatgaaacggctggttg 3') and primer B (5'ctagatttctgggtaagaggg 3') designed to specifically amplify the cathepsin S cDNA. The resulting 900 bp DNA fragment was subcloned into pGEM-T (Promega) and sequenced to confirm its identity. This construct was used for all subsequent manipulations. This procedure is typical for  
15 cloning of known genes and is established in its field.

Human Pre-Pro-Cat S was removed from pGem-T vector (Promega, 2800 Woods Hollow Rd, Madison, WI 53711) by digestion with restriction enzyme SacII, followed by treatment with T4 DNA polymerase to generate a blunt end, and a second restriction  
20 enzyme digest with SalI. It was subcloned into pFastBac1 donor plasmid (GibcoBRL, 8717 Grovemont Cr., Gaithersburg, MD 20884) which had been cut with restriction enzyme BamHI and blunt-ended and then cut with restriction enzyme SalI. The ligation mixture was used to transform DH5a competent cells (GibcoBRL) and plated on LB plates containing 100ug/ml ampicillin. Colonies were grown in overnight cultures of LB  
25 media containing 50ug/ml Ampicillin, plasmid DNA isolated and correct insert confirmed by restriction enzyme digestion. Recombinant pFastBac donor plasmid was transformed into DH10Bac competent cells (GibcoBRL). Large white colonies were picked from LB plates containing 50ug/ml kanamycin, 7ug/ml gentamicin, 10ug/ml tetracycline, 100ug/ml Bluo-gal, and 40ug/ml IPTG. DNA was isolated and used to  
30 transfect Sf9 insect cells using CellFECTIN reagent (GibcoBRL). Cells and supernatant



were harvested after 72 hours. Viral supernatant was passaged twice and presence of Cat S confirmed by PCR of the supernatant.

5 SF9 cells were infected with recombinant baculovirus at a MOI of 5 for 48-72 hrs. Cell pellet was lysed and incubated in buffer at pH 4.5 at 37 for 2 hours to activate Cat S from pro-form to active mature form (Bromme, D & McGrath, M., Protein Science, 1996, 5:789-791.) Presence of Cat S was confirmed by SDS-PAGE and Western blot using rabbit anti-human proCat S.

#### 10 Inhibition of Cathepsin S

Human recombinant cathepsin S expressed in Baculovirus is used at a final concentration of 10 nM in buffer. Buffer is 50 mM Na acetate, pH 6.5, 2.5 mM EDTA, 2.5 mM TCEP. Enzyme is incubated with either compound or DMSO for 10 min at 37 °C. Substrate 7-amino-4-methylcoumarin, CBZ-L-valyl-L-valyl-L-arginineamide (custom synthesis by  
15 Molecular Probes) is diluted to 20 uM in water (final concentration of 5 M), added to assay and incubated for additional 10 minutes at 37 °C. Compound activity is measured by diminished fluorescence compared to DMSO control when read at 360 nm excitation and 460 nm emission.

20

The provided examples were evaluated for inhibition of cathepsin S in the above assay. With the exception of Morpholine-4-carboxylic acid [(R)-1-(4-cyano-1-methyl-piperidine-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-amide, all had IC<sub>50</sub> values of 100 nM or below.

25

#### Inhibition of Cathepsin L

This protocol is identical to that described above for measuring Cathepsin S inhibition with the exception that human Cathepsin L (Athens Research, Georgia) is substituted for  
30 Cathepsin S.


The provided examples were evaluated for inhibition of cathepsin L in the above assay. All had  $IC_{50}$  values of about or greater than 1000 nM..

- With the exception of Morpholine-4-carboxylic acid [(R)-1-(4-cyano-1-methyl-
- 5 piperidine-4-ylcarbamoyl)-4,4-dimethyl-hexyl]-amide, the examples above demonstrate between a 50 and 5000 fold selectivity for cathepsin S over cathepsin L based on these molecular assays (calculated as cathepsin L  $IC_{50}$  / cathepsin S  $IC_{50}$ ).

**What is Claimed is:**


1. A compound of the formula (I) or (II) :

5



wherein X in each case is chosen from

10



R1 is chosen from hydrogen or alkyl branched or straight chain alkyl, each carbon atom  
 15 in the chain is optionally replaced with one to three heteroatoms chosen from O, S, and  
 N-R2 wherein R2 is hydrogen or alkyl;

and wherein R1 is optionally further substituted by one or more alkoxy, amine, halogen,  
 carbocycle, heteroaryl or heterocycle;


20

or the pharmaceutically acceptable salts thereof.


2. The compound according to claim 1 wherein:

5

in the formula (I)



X is chosen from



R1 is chosen from hydrogen or C1-10 alkyl branched or straight chain C1-10 alkyl, each carbon atom in the chain is optionally replaced with one to three heteroatoms chosen from O, S, and N-R2 wherein R2 is hydrogen or C1-5 alkyl;


15

and wherein R1 is optionally further substituted by one or more C1-5 alkoxy, amine, heterocycle or halogen.


20 3. The compound according to claims 1 or 2 wherein of R1 is C1-5 alkyl.

4. The compound according to any of claims 1, 2 or 3 wherein of R1 is C1-3 alkyl, preferably methyl.


5 5. The compound according to claims 1 or 2 wherein R1 is chosen from:



6. The compound according to any of claims 1-5 wherein the compound of the formula  
 10 (I) is the (S) enantiomer which possesses a natural amino acid configuration at the indicated chiral carbon below




15 7. A compound chosen from



or the pharmaceutically acceptable salts thereof.

5





8. A compound or the pharmaceutically acceptable salts thereof wherein the compound is:




wherein the indicated chiral carbon is the (S) enantiomer which possesses a natural amino acid configuration.

5


9. A compound chosen from:



10



and



;

or the pharmaceutically acceptable salts thereof.

5

10. Use of the compounds defined in claims 1 to 9 for treating a disease or condition chosen from:

- 10 rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, Grave's disease, myasthenia gravis, scleroderma, glomerulonephritis, dermatitis including contact and atopic dermatitis, insulin-dependent diabetes mellitus, endometriosis, asthma, Alzheimer's disease and atherosclerosis.

- 15 11. Use of the compounds defined in claims 1 to 9 for preparing a pharmaceutical composition which is suitable for the treatment of an autoimmune disease or condition, disorders associated with inappropriate autoimmune responses, T-cell mediated immune responses or extracellular proteolysis mediated by cathepsin S.



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/006554

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/66 C07D413/12 A61K31/4468 A61K31/536 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>US 6 420 364 B1 (SPERO DENICE MARY ET AL) 16 July 2002 (2002-07-16) cited in the application column 1, line 1 - column 84, line 46 examples 1-61,64,69,81-83,89 column 147, line 7 - column 149, line 67 claims 1-37</p> <p style="text-align: center;">----- -/--</p>	1-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

20 August 2004

Date of mailing of the international search report

30/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Papathoma, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/006554

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>US 6 525 052 B2 (SUN SANXING ET AL)  25 February 2003 (2003-02-25)  cited in the application  column 3, line 53 - column 60, line 10  column 36; examples A1,A2  column 37; example A7  column 42; example A40  column 50; example B36  column 51; example B38  column 53, line 10 - column 58, line 67;  examples C1-C24,C35-C39  column 68, line 49 - column 71, line 19  column 80, line 1 - column 176, line 67;  claims 1-11; examples 12,18,36-38</p>	1-11
Y	<p>WO 02/100849 A (BOEHRINGER INGELHEIM  PHARMA) 19 December 2002 (2002-12-19)  page 7, line 15 - page 30, line 62  page 71, line 8 - page 131, line 21;  claims 1-31</p>	1-11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/006554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6420364	B1	16-07-2002	AU 4569401 A 22-03-2002
			BG 107585 A 28-11-2003
			BR 0113740 A 24-06-2003
			CA 2417177 A1 14-03-2002
			CN 1471511 T 28-01-2004
			CZ 20030603 A3 18-06-2003
			EP 1322613 A1 02-07-2003
			HU 0303934 A2 28-04-2004
			JP 2004508356 T 18-03-2004
			NO 20031065 A 07-03-2003
			SK 2862003 A3 05-08-2003
			US 2002058809 A1 16-05-2002
			WO 0220485 A1 14-03-2002
			US 2003216383 A1 20-11-2003
			US 2004006078 A1 08-01-2004
			US 2003225271 A1 04-12-2003
			US 2003225270 A1 04-12-2003
			US 2003232826 A1 18-12-2003
			US 2002137932 A1 26-09-2002
			AT 244235 T 15-07-2003
			AU 7081800 A 17-04-2001
			BG 106483 A 31-10-2002
			BR 0013966 A 15-06-2004
			CA 2385130 A1 22-03-2001
			CN 1384830 T 11-12-2002
			CZ 20020844 A3 12-06-2002
			DE 60003702 D1 07-08-2003
			DE 60003702 T2 22-04-2004
			DK 1218372 T3 20-10-2003
			EE 200200132 A 15-12-2003
			EP 1218372 A1 03-07-2002
			ES 2199856 T3 01-03-2004
			HU 0302380 A2 01-03-2004
			JP 2003529546 T 07-10-2003
			NO 20021207 A 12-03-2002
			PT 1218372 T 28-11-2003
			SI 1218372 T1 31-12-2003
			SK 4902002 A3 10-09-2002
			WO 0119816 A1 22-03-2001
US 6525052	B2	26-09-2002	US 6420364 B1 16-07-2002
			US 2002137932 A1 26-09-2002
			US 2003216383 A1 20-11-2003
			US 2004006078 A1 08-01-2004
			US 2003232826 A1 18-12-2003
			AU 4569401 A 22-03-2002
			BG 107585 A 28-11-2003
			BR 0113740 A 24-06-2003
			CA 2417177 A1 14-03-2002
			CN 1471511 T 28-01-2004
			CZ 20030603 A3 18-06-2003
			EP 1322613 A1 02-07-2003
			HU 0303934 A2 28-04-2004
			JP 2004508356 T 18-03-2004
			NO 20031065 A 07-03-2003
			SK 2862003 A3 05-08-2003
			US 2002058809 A1 16-05-2002
			WO 0220485 A1 14-03-2002

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/006554

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6525052	B2	US 2003225271 A1	04-12-2003
		US 2003225270 A1	04-12-2003
WO 02100849	A	19-12-2002	
		CA 2449192 A1	19-12-2002
		EP 1399431 A2	24-03-2004
		WO 02100849 A2	19-12-2002
		US 2003119827 A1	26-06-2003

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**